Clinical Trial Update: Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Efbemalenograstim Alfa for primary and secondary prevention of febrile neutropenia in patients with solid tumors receiving che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Efbemalenograstim Alfa (efbemalenograstim alfa)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens | Phase 2 | Status: RECRUITING